The Duration of Azithromycin use for Outpatients in a Public Hospital in Alkharj

Nehad J. Ahmed

1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Aim: The present study aims to explore the appropriateness of azithromycin use duration in the outpatient setting in a public hospital.

Methodology: The present study included a review of the electronic prescriptions in the outpatient setting in a public hospital in Alkharj between January 2018 till June 2018.

Results: The total number of outpatients who received was 541 patients. Most of these patients received azithromycin as a suspension (55.64%). In general, most of the patients received azithromycin for 3 days (88.17%) followed by 5 days (9.98%).

Conclusion: The study showed that azithromycin was prescribed commonly and that the duration of azithromycin treatment in the hospital was for 3 days for the majority of patients. It is important to monitor the appropriateness of prescribing azithromycin and to educate the patients about the use of their drugs.

Keywords: Antibiotic; azithromycin; duration; outpatient; use.
concentrations are thought to be more indicative of the clinical efficacy of macrolides [4]. Antibiotics are used to treat infections that are caused by bacteria and are usually given as a short course for 1–2 weeks and then stopped [5]. Azithromycin is used commonly because it has a potential immunomodulatory and anti-inflammatory action in several respiratory diseases [6–8]. The usual dose is 500mg a day for 3 to 10 days depending on the infection being treated [9].

There are numerous side effects for azithromycin use. Common side effects of azithromycin include diarrhea, blistering, crust ing, irritation, itching, or reddening of the skin, loose stools, cracked and scaly skin, fever and swelling [10]. Furthermore, azithromycin might increase the risk of life-threatening ventricular arrhythmias or cardiac arrest due to corrected QT interval prolongation [11], and this risk might be enhanced in the presence of other drugs known to prolong corrected QT interval, such as hydroxychloroquine [12-14].

Medication interactions may change how the drugs work or increase the risk for serious side effects. Numerous drugs interacts with azithromycin particularly the drugs that may affect the heart rhythm that leads to QT prolongation such as amiodarone, hydroxychloroquine [15].

Azithromycin should be used wisely with the correct duration in order to decrease its adverse events and its toxicity. Therefore, the present study aims to aim to explore the appropriateness of azithromycin use duration in the outpatient setting in a public hospital.

2. METHODOLOGY

The present study included a review of the electronic prescriptions in the outpatient setting in King Khaled Hospital in Al-kharj to explore the prescribed dosage forms of azithromycin and to describe the duration of different dosage forms of azithromycin that were used in the hospital during the period of 6 months between January 2018 till June 2018. Al Kharj is a governorate in central Saudi Arabia. It is one of the important governorates in the Kingdom of Saudi Arabia and is located in the southeast of the capital Riyadh.

All of the prescriptions in the outpatient pharmacy that included azithromycin were included in the study. The prescriptions that didn’t include azithromycin and the prescription that were prescribed for inpatients were excluded from the study.

The data were collected after the approval of the study from hospital ethical committee. The data was processed using Microsoft Excel and the descriptive data was represented as frequencies and percentages.

3. RESULTS AND DISCUSSION

The total number of outpatients who received was 541 patients. Most of these patients received azithromycin as a suspension (55.64%). Table 1 shows the dosage forms of the prescribed azithromycin.

Table 2 shows the duration of azithromycin tablet use in the hospital. Most of the patients received azithromycin tablet for 3 days (76.67%) followed by 5 days (20.83%).

Table 3 shows the duration of azithromycin suspension use in the hospital. Most of the patients received azithromycin suspension for 3 days (97.34%), followed by 5 days (1.33%).

Table 4 shows the duration of azithromycin use (for all dosage forms) in the hospital. In general, Most of the patients received azithromycin for 3 days (88.17%) followed by 5 days (9.98%).

The study showed that generally the duration of azithromycin treatment in the hospital was for 3 days. The tablets and suspension of azithromycin are usually taken with or without food once a day for 1–5 days [16].

| Table 1. The dosage forms of the prescribed azithromycin |
|-------------|-------------|-------------|
| Dosage form | Number      | Percentage  |
| ZITHROMAX 250 mg Tablet | 240 | 44.36 |
| ZITHROMAX 200 mg/5 ml Suspension | 301 | 55.64 |
| Total      | 541         | 100.00      |
Table 2. The duration of azithromycin tablets uses in the hospital

| Number of Days | Number of prescriptions | Percentage |
|----------------|-------------------------|------------|
| 3 Day(S)       | 184                     | 76.67      |
| 4 Day(S)       | 1                       | 0.41       |
| 5 Day(S)       | 50                      | 20.83      |
| 7 Day(S)       | 3                       | 1.25       |
| 10 Day(S)      | 1                       | 0.41       |
| 30 Day(S)      | 1                       | 0.41       |
| Total          | 240                     | 100        |

Table 3. The duration of azithromycin suspensions uses in the hospital

| Number of Days | Number of prescriptions | Percentage |
|----------------|-------------------------|------------|
| 3 Day(S)       | 293                     | 97.34      |
| 4 Day(S)       | 3                       | 1.00       |
| 5 Day(S)       | 4                       | 1.33       |
| 7 Day(S)       | 1                       | 0.33       |
| Total          | 301                     | 100        |

Table 4. The duration of azithromycin use in the hospital

| Number of Days | Number of prescriptions | Percentage |
|----------------|-------------------------|------------|
| 3 Day(S)       | 477                     | 88.17      |
| 4 Day(S)       | 4                       | 0.74       |
| 5 Day(S)       | 54                      | 9.98       |
| 7 Day(S)       | 4                       | 0.74       |
| 10 Day(S)      | 1                       | 0.18       |
| 30 Day(S)      | 1                       | 0.18       |
| Total          | 541                     | 100        |

The duration of therapy for some diseases is 5 days such as tonsillitis, pharyngitis, skin infection, chronic obstructive pulmonary disease and bronchitis [17]. The duration of therapy for some diseases is such as Lyme disease, pelvic inflammatory disease and community-acquired pneumonia [17]. For other diseases the duration is 3 days such as sinusitis [17].

Duration of treatment varies with indication and severity. Several days of treatment is generally appropriate in respiratory tract infections and several months in mycobacterial infections. Guidelines should be consulted for detailed recommendations [18].

The duration could be changed from one place to another. Casey and Pichichero stated that in the United States, a 5-day regimen of azithromycin is approved for treatment of Group A Streptococcal tonsillopharyngitis in adults; outside the United States, a 3-day regimen is approved [19].

The main limitation in the study was that there were no indications in the electronic records so the impact of various durations of the drug prescription on the patients is not included in the study.

4. CONCLUSION

The study showed that azithromycin was prescribed commonly and that the duration of azithromycin treatment in the hospital was for 3 days for the majority of patients. It is important to monitor the appropriateness of prescribing azithromycin and to educate the patients about the use of their drugs.

DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely
no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL

The data were collected after the approval of the study from hospital ethical committee. Patients’ written consent has been collected and preserved by the author(s).

ACKNOWLEDGEMENT

This Publication was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis. 1991; 10(10):807-812.
2. Singlas E. Clinical pharmacokinetics of azithromycin. Pathol Biol. 1995;43(6):505-511.
3. Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res. 2002;46(6):545-550.
4. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents. 2001;18(1):S11-S15.
5. NHS. Azithromycin patient information leaflets; 2020. Available: http://www.sthk.nhs.uk/patients-visitors/Documents/Patient%20Information%20Leaflets/Azithromycin.pdf
6. Zhang Y, Dai J, Jian H, Lin J. Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta-analysis of randomized controlled trials. Microbiol Immunol. 2019;63(9):343–9.
7. Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M. Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents. 2018;51(6):918–24.
8. Kuo C-H, Lee M-S, Kuo H-F, Lin Y-C, Hung C-H. Azithromycin suppresses Th1- and Th2-related chemokines IP-10/MDC in human monocyctic cell line. J Microbiol Immunol Infect. 2019;52(6):872–9.
9. NHS. Azithromycin; 2020. Available: https://www.nhs.uk/medicines/azithromycin/
10. Drugs.com. Azithromycin; 2020. Available: https://www.drugs.com/sfx/azithromycin-side-effects.html
11. Ray WA, Murray KT, Hall K, Arboagast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-1890
12. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-1041.
13. Nguyen LS, Dolladille C, Drici MD, Feniloux C, Alexandre J, Mira JP, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: An analysis of the World Health Organization Pharmacovigilance Database. Circulation. 2020;142(3):303-305.
14. Rosenberg ES, DuFort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493-2502.
15. Webmd. Azithromycin; 2020. Available: https://www.webmd.com/drugs/2/drug-1527-3223/azithromycin-oral/azithromycin-250-500-mg-oral/details
16. Medlineplus. Azithromycin; 2020. Available: https://medlineplus.gov/druginfo/meds/a697037.html#how
17. Drugs.com. Azithromycin dosage; 2020. Available: https://www.drugs.com/dosage/azithromycin.html
18. Antibiotic Expert Groups. Therapeutic guidelines: antibiotic. Version 15. Melbourne: Therapeutic Guidelines Limited; 2014. [Google Scholar]
19. Casey JR, Pichichero ME. Higher Dosages of Azithromycin Are More Effective in Treatment of Group A Streptococcal Tonsillopharyngitis. Clin Infect Dis. 2005; 40(12):1748–1755.

© 2021 Ahmed; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/65553